Home > Haematology > EHA 2022 > Transfusion-dependent β-thalassemia patients continue to benefit from luspatercept after 3 years of treatment.

Transfusion-dependent β-thalassemia patients continue to benefit from luspatercept after 3 years of treatment.

Presented By
Prof. Maria Capellini, University of Milan, Italy
Conference
EHA 2022
Trial
Phase 3, BELIEVE
Continued treatment with luspatercept, for up to 3 years, allowed more patients to experience a reduction in red blood cell transfusion burden and an increase in time between transfusions, longer-term results from the BELIEVE trial demonstrate. β-thalassemia is a hereditary blood disorder characterised by impaired haemoglobin (Hb) production and chronic anaemia of varying severity [1]. Patients with transfusion-dependent β-thalassemia require lifelong regular red blood cell transfusions for survival as well as iron chelation therapy to manage iron overload [2]. However, many patients still experience multiple morbidities due to iron toxicity. There is also a need for treatments that lessen the burden of transfusions. Luspatercept is a recombinant fusion protein that enhances late-stage erythropoiesis and improves haemoglobin levels in patients with β-thalassemia [3]. Recently, the primary analysis of the phase 3 BELIEVE trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on